若生智能
Drug Database
PI

pitavastatin + valsartan (Livalsartan / Livasartan)

✓ Approved

JW Pharmaceutical · AGTR1 · 小分子

什么是 pitavastatin + valsartan？

pitavastatin + valsartan 是一种小分子，由JW Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Livalsartan, Livasartan
公司JW Pharmaceutical
药物类别小分子
分子靶点AGTR1, HMGCR
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, JW Pharmaceutical

作用机制

分子靶点

pitavastatin + valsartan 作用于 2 个分子靶点：

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pitavastatin + valsartan 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedJournal of cardiovascular development and disease2026-07-27

Sacubitril/Valsartan for Prevention of Cancer Therapy-Related Cardiac Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Lopez-Arevalo Hugo H, Mautong Hans H, Nubla Adrian A, Dispagna Marco Antonio MA et al.

Cancer therapy-related cardiac dysfunction (CTRCD) is a significant complication of anthracycline-based regimens and anti-HER2 agents. Global longitudinal strain (GLS) detects subclinical dysfunction before ejection fraction decline and is recommended by the 2022 ESC guidelines for surveillance. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has shown cardioprotective potential in recent trials. Following PRISMA 2020 guidelines, we searched PubMed, EMBASE, and Cochrane CENTRAL through February 2026. Three RCTs met eligibility criteria (n= 350; PROSPERO: CRD420261383124): Hsu 2025 (n = 100, 12 months), PRADA II 2025 (n = 138, 18 months), and SARAH 2025 (n = 112, 6 months). Random-effects meta-analysis used REML with Hartung-Knapp-Sidik-Jonkman adjustment. The pooled mean difference in final GLS significantly favored sacubitril/valsartan (MD -0.95%; 95% CI -1.40 to -0.50; p = 0.012; I2 = 0%). Final LVEF showed a consistent trend (MD +1.53%; 95% CI -0.47 to 3.52; p = 0.082; I2 = 0%). Hypotension was numerically more frequent with sacubitril/valsartan (OR 5.10; 95% CI 0.52-49.50; p = 0.091). Sacubitril/valsartan initiated during anthracycline therapy was associated with significant GLS preservation. However, GLS is a surrogate imaging marker and hard clinical events were rare or absent, so the modest effect magnitude and limited number of trials warrant cautious interpretation; the clinical benefit remains uncertain and requires confirmation in adequately powered trials with hard clinical endpoints.

PMID 42505901
阅读全文 →
PubMedJournal of environmental management2026-07-26

Hybrid green wall - ozonation system for greywater and rainwater reclamation in a residential building: technical performance and social insights.

Mendoza Esther E, Herrán-Morueco Èric È, Riva Massimiliano M, Beral Henry H et al.

Growing water scarcity calls for sustainable and decentralized strategies to reduce demand for freshwater resources. Greywater reuse is a promising option, though concerns about pathogens and organic micropollutants (OMPs) necessitate effective treatment. This study evaluates a full-scale system integrating a green wall with ozonation, installed on a residential building in Sant Quirze del Vallès (Barcelona, Spain), for greywater and rainwater treatment and reuse in toilet flushing. Over one year, the green wall achieved high removal of COD (84%), BOD5 (96%), TOC (87%), TSS (94%), and ammonium (>99%), with ozonation providing additional polishing and ensuring microbial safety (E. coli below the detection limit). Several OMPs, including caffeine, benzotriazole, and tramadol, were effectively removed by the green wall, while ozonation addressed more persistent compounds such as DEET or valsartan. The treated effluent consistently met Spanish quality standards for non-potable reuse. Social acceptance was assessed through resident surveys and stakeholder interviews. While participants acknowledged the environmental value of water reuse, acceptance was influenced by practical concerns (odour, noise or water colour) and trust in the managing entity. Findings highlight the need to complement strong technical performance with effective communication and reliable maintenance to foster long-term adoption of such nature-based and hybrid solutions.

PMID 42501640
阅读全文 →
PubMedFrontiers in endocrinology2026-07-25

A multi-center, open-label, observational study to evaluate the efficacy and safety of LivaloZet® tablets in patients with dyslipidemia and metabolic syndrome: PIVOT study protocol.

Joung Kyong Hye KH, Ku Bon Jeong BJ

Dyslipidemia accompanied by metabolic syndrome substantially elevates cardiovascular risk by clustering multiple risk factors, including abdominal obesity, hypertension, hyperglycemia, and atherogenic dyslipidemia. The prevalence of both conditions is rising in Korea, underscoring the need for effective and metabolically safe lipid-lowering therapy. LivaloZet® Tablet (pitavastatin/ezetimibe fixed-dose combination) addresses this need by combining complementary cholesterol-lowering mechanisms with the glucose-neutral profile of pitavastatin. The PIVOT study is a multi-center, non-interventional, prospective observational study enrolling up to 10,000 Korean adult patients with dyslipidemia accompanied by metabolic syndrome who have been prescribed LivaloZet® Tablets (pitavastatin/ezetimibe 2/10 mg or 4/10 mg) by their treating physician as part of routine clinical care. Metabolic syndrome is defined according to the modified NCEP-ATP III criteria for the Asian population. Assessments are conducted at baseline, Week 24, and Week 48. The primary endpoint is the percent change in low-density lipoprotein cholesterol (LDL-C) from baseline at Week 24. Secondary endpoints include LDL-C changes at Week 48, changes in the full lipid panel, and LDL-C target achievement rates by cardiovascular risk group. Exploratory endpoints encompass glucose metabolism parameters (HbA1c, HOMA-IR, HOMA-β), medication adherence and persistence, and high-sensitivity C-reactive protein. Safety is assessed through adverse events, laboratory tests, and vital signs, including systematic monitoring of AST, ALT, and creatine kinase for statin-related hepatotoxicity and myopathy. The study was approved by the Institutional Review Board of Chungnam National University Hospital (2025-07-065) and is registered at ClinicalTrials.gov (NCT07523971). The PIVOT study will generate prospective large-scale real-world evidence on the LDL-C-lowering effectiveness and safety patterns associated with use of a pitavastatin/ezetimibe fixed-dose combination in Korean patients with dyslipidemia accompanied by metabolic syndrome. The inclusion of glucose metabolism and inflammatory markers will provide descriptive information on the metabolic safety profile of this regimen. As a non-randomized, single-arm observational study, this design cannot establish causal effects or comparative efficacy versus other lipid-lowering regimens. Findings should be interpreted descriptively, acknowledging potential confounding by indication, selection bias, and inter-laboratory variability.

PMID 42500128
阅读全文 →
PubMedAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026-07-25

Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study.

Riaz Munaza M, Smith Steven M SM, Winchester David E DE, Dietrich Eric A EA et al.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and sacubitril/valsartan (SAC/VAL), an angiotensin receptor-neprilysin inhibitor, are both US Food and Drug Administration-approved and guideline-recommended therapies for heart failure with reduced ejection fraction (HFrEF). While each has demonstrated significant reductions in cardiovascular morbidity and mortality, direct comparative evidence remains limited, particularly in relation to patients' diabetes status. To compare the effectiveness of SAC/VAL versus SGLT2i in preventing HF-related and all-cause hospitalizations among patients with HFrEF, with or without diabetes, using real-world data from the MarketScan® Research databases. This new-user, active-comparator cohort study using MarketScan® Commercial and Medicare databases (2019-2023) identified patients with HFrEF by using International Classification of Diseases codes. Patients who initiated SAC/VAL or SGLT2i treatment were included, with the index date defined as the first prescription fill. Continuous health plan enrollment ≥ 6 months prior to HFrEF diagnosis through the index date was required. To balance baseline characteristics between groups, we applied stabilized inverse probability of treatment weighting (IPTW). Cox proportional hazards models compared risks of HF-related and all-cause hospitalizations in cohort analyses defined by diabetes status, diagnosis, and antidiabetic medications. After IPTW, the study included 7406 patients initiating SAC/VAL and 5101 patients initiating SGLT2i. Among patients with diabetes, there were no significant differences in the risks of HF-related hospitalization (adjusted hazard ratio [aHR] 1.13, 95% confidence interval [CI] 0.98-1.30) or all-cause hospitalization (aHR 0.99, 95% CI 0.90-1.09) between medication groups. In contrast, among patients without diabetes, initiation of SAC/VAL was associated with significantly lower risks of HF-related hospitalization (aHR 0.65, 95% CI 0.56-0.76) and all-cause hospitalization (aHR 0.69, 95% CI 0.62-0.77). In a real-world cohort of patients with HFrEF and without diabetes, but not those with diabetes, SAC/VAL initiation was associated with reduced risks of HF-related and all-cause hospitalizations compared with SGLT2i initiation. These findings provide supportive evidence that may inform clinicians when selecting therapy for patients with HFrEF.

PMID 42501250
阅读全文 →
PubMedPharmacology & therapeutics2026-07-24

Biomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring.

Li Yafeng Y, Song Wenzhu W, Huan Chengyu C, Xu Keman K et al.

Cardiovascular-kidney-metabolic (CKM) syndrome, formally defined by the American Heart Association in 2023, affects approximately 90% of US adults, who meet criteria for stage 1 or higher. The rapid convergence of multiple drug classes on CKM pathways-SGLT2 inhibitors, finerenone, GLP-1 receptor agonists, ARNI, and interleukin-directed therapies-has created an urgent need for pharmacologically grounded frameworks that guide drug selection, interpret biomarker responses, and monitor target engagement across interconnected organ systems. This review proposes a three-dimensional biomarker-guided approach to precision pharmacotherapy in CKM syndrome. In the organ-specific dimension, we map key biomarkers to their corresponding drug targets and elucidate the molecular mechanisms underlying drug-biomarker interactions: SGLT2 inhibitors attenuate myocardial injury through metabolic substrate shifting toward ketone body utilization and, based on preclinical evidence, NHE1 inhibition; neprilysin selectivity of sacubitril/valsartan explains the differential natriuretic peptide response; and tubuloglomerular feedback mediates the renoprotective hemodynamic effects of SGLT2 inhibitors. In the pathway-specific dimension, we identify cross-system biomarkers-hs-CRP, IL-6, galectin-3, GDF-15, and FGF21-that reveal shared druggable targets spanning the IL-1β/NLRP3 inflammasome axis (canakinumab, colchicine), IL-6 trans-signaling (ziltivekimab), and FGF21/β-klotho metabolic signaling. In the temporal dimension, we demonstrate how serial biomarker trajectories serve as pharmacodynamic readouts that distinguish therapeutic drug effects from disease progression, including the initial eGFR dip with SGLT2 inhibitors and natriuretic peptide changes during combination therapy. Central to this framework is the concept of "pharmacological phenotyping"-using multi-biomarker panels to define drug-responsive pathophysiological states that directly inform therapeutic selection, analogous to companion diagnostics in oncology. We further present a comprehensive drug-biomarker interaction matrix with pharmacological rationale and analyze the emerging drug development pipeline, including RNA-based Lp(a) therapeutics, FGF21 analogues, galectin-3 inhibitors, and in vivo CAR-T anti-fibrotic approaches. This framework provides a practical roadmap for biomarker-guided precision pharmacotherapy in CKM syndrome.

PMID 42492739
阅读全文 →
PubMedPakistan journal of pharmaceutical sciences2026-07-23

Formulation and evaluation of sustained-release pitavastatin-loaded chitosan nanoparticles for enhanced anti-hyperlipidemic activity.

Arshad Amina A, Zaman Muhammad M, Riaz Humayun H, Haider Muhammad Sajjad MS et al.

Pitavastatin (PVN), a BCS class-II drug, exhibits poor aqueous solubility leading to limited oral bioavailability and therapeutic efficacy. This study aimed to enhance the solubility and anti-hyperlipidemic efficacy of Pitavastatin (PVN) by encapsulating it in chitosan-based polymeric nanoparticles. Pitavastatin-loaded chitosan nanoparticles (NPs) were prepared using the ionic gelation method. Formulations were characterized by particle size, zeta potential, drug loading, In-vitro drug release and surface morphology. Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), thermal analysis (TGA and DSC), ex-vivo intestinal permeability and in-vivo pharmacodynamic analysis were also performed. The size of PVN-loaded NP ranged from 219.9±1.11 to 292.7±2.29 nm with PDI 0.2-0.4, surface charge of +28.4 ± 0.43 to 32.5 ± 1.02 mV and entrapment efficiency 65±1.12-93±1.23%. Solubility in different media (PBS (pH 6.8), 0.1N HCl (pH 1.2) and distilled water showed a 56-102-fold increase compared to PVN. SEM analysis revealed a smooth surface and spherical geometry of the NP. FTIR analysis confirmed that there was no physicochemical interaction between PVN and chitosan in NP formulations (NP1-NP5). XRD and thermal analysis indicated the amorphous nature of PVN-loaded NP. In-vitro drug release from NP formulations (NPI-NP5) ranged from 80.97±4.80 to 81±3.90% indicating sustained release, while ex-vivo intestinal permeability was 1.5-fold higher than PVN. The optimized formulation (NP1) followed Higuchi release model, indicating Fickian diffusion. Pharmacodynamic analysis of lipid profiles in hyperlipidemic albino rats suggested that NP1 reduced low-density lipoprotein (LDL) by 33±1.24 %, total cholesterol by 29±2.13% and triglycerides by 23±1.21%, showing better results than PVN. Chitosan-based Pitavastatin nanoparticles successfully enhanced drug solubility and provided sustained release, leading to improved ex-vivo permeability and greater in-vivo anti-hyperlipidemic activity in albino rats. This approach represents a promising strategy for enhancing therapeutic potential of Pitavastatin.

PMID 42489300
阅读全文 →

注册免费账户还可查看另外 7345 篇文献

免费注册查看全部文献 →

了解更多pitavastatin + valsartan